News & Videos - SYNAIRGEN ORD 1P

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta to treat or prevent severe viral lung infections, today announces topline data for participants treated with SNG001 in the US National Institutes of Health (NIH)/ AIDS Clinical Trials Group (ACTG)-led ACTIV-2 Phase 2 adaptive platform trial for COVID-19. Between February and August 2021, 221 symptomatic,...

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces it will present its positive findings from the analysis of data from 60 and 90-day follow-up visits from the Phase 3 SPRINTER trial in patients hospitalised with COVID-19 at IDWeek 2022 to be held 19-23 October 2022 in Washington, D.C. The analysis shows that when compared to placebo, SNG001 reduced the...

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces positive data from additional assessments of lung sputum samples from its Phase 2 clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection ( SG015, NCT03570359 ). In early 2020, due to the emergence of SARS-CoV-2,...

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19. SPRINTER (SG018; NCT04732949) was a global, randomised, placebo-controlled, double-blind clinical trial assessing the efficacy and safety...

Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference PR Newswire SOUTHAMPTON, England, April 5, 2022 SOUTHAMPTON, England , April 5, 2022 /PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that further analysis of its Phase 3 SPRINTER trial data...

Synairgen announces global strategic partnership with Ashfield Engage PR Newswire SOUTHAMPTON, United Kingdom, Jan. 6, 2022 SOUTHAMPTON, United Kingdom , Jan. 6, 2022 /PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, today announces a partnership with global experts in strategic...

Synairgen Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference - In vitro data demonstrate antiviral activity of SNG001 against multiple variants of SARS-CoV-2 - Clinical biomarker data show inhaled SNG001 stimulates lung antiviral responses PR Newswire SOUTHAMPTON, United Kingdom, Dec. 7, 2021 SOUTHAMPTON, United Kingdom , Dec. 7, 2021 /PRNewswire/ -- Synairgen plc (LSE: SNG), the...

Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients - Target of 610 patients from 17 countries achieved - Synairgen remains on track for top line results early in 2022 PR Newswire SOUTHAMPTON, United Kingdom, Nov. 11, 2021 SOUTHAMPTON, United Kingdom , Nov. 11, 2021 /PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum anti-viral protein...

Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen a nnounces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK – 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta (IFN-beta) for the treatment of severe viral lung infections, has been informed that the external data safety monitoring...

Synairgen plc (‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, is pleased to announce the appointment of Theodora Harold as an independent Non-Executive Director of the Company and Chair of the Audit Committee with immediate effect. Theodora has over 20 years’ experience in the biotech sector and is currently CEO of Crescendo Biologics Ltd....

Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 20 2 1 Scaling up and p reparing for Phase III COVID -19 trial data read-out Webcast today at 13:00 BS T Southampton, UK – 30 September 2021 : Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, today announces its unaudited interim results for the six months ended 30 June 2021. Richard Marsden, CEO of Synairgen, said: “The need for an effective ,...

Synairgen plc (‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, is pleased to announce the appointment of Theodora Harold as an independent Non-Executive Director of the Company and Chair of the Audit Committee with immediate effect. Theodora has over 20 years’ experience in the biotech sector and is currently CEO of Crescendo Biologics Ltd....

Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 20 2 1 Scaling up and p reparing for Phase III COVID -19 trial data read-out Webcast today at 13:00 BS T Southampton, UK – 30 September 2021 : Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, today announces its unaudited interim results for the six months ended 30 June 2021. Richard Marsden, CEO of Synairgen, said: “The need for an effective ,...

Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants SNG001 shows potent antiviral activity against SARS-CoV-2 variants Demonstrates broad-spectrum antiviral activity of host - targeted antiviral treatment delivered directly into the lungs Southampton, UK – 24 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing an inhaled formulation of...

Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants SNG001 shows potent antiviral activity against SARS-CoV-2 variants Demonstrates broad-spectrum antiviral activity of host - targeted antiviral treatment delivered directly into the lungs Southampton, UK – 24 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing an inhaled formulation of...

Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 20 20 Significant p rogress continues towards a treatment for COVID- 19 Southampton, UK – 12 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces its preliminary statement of audited results for the year ended 31 December 2020. Highlights (including post...

Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 20 20 Significant p rogress continues towards a treatment for COVID- 19 Southampton, UK – 12 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces its preliminary statement of audited results for the year ended 31 December 2020. Highlights (including post...

Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial The vast majority of Home Cohort patients experienced mild disease - only two patients were hospitalised during the treatment period , both on placebo Home Cohort patients successfully self-administered SNG001 The degree of breathlessness at start of treatment...

Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial The vast majority of Home Cohort patients experienced mild disease - only two patients were hospitalised during the treatment period , both on placebo Home Cohort patients successfully self-administered SNG001 The degree of breathlessness at start of treatment...

Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with...